ALL4IBD demonstrated a significant improvement in patients' quality of care. In a pragmatic randomized trial at Mount Sinai Medical Center (MSMC), baseline e- PROs were measured using online questionnaires delivered through the app that assessed health literacy, disease severity, general health status, and demographic information. Patients using ALL4IBD could update their e-PRO information and receive a disease summary. Patients could also communicate over the ALL4IBD program and discuss results with providers.

At baseline, patients in the intervention arm reported a mean quality of life score of 30.3 ± 11.3. The last available follow-up QoL scores showed improvement among patients using ALL4IBD to 25.3 ± 11.3 (p < 0.001). Patients engaging with ALL4IBD reported more equitable participation in their care decision-making process, and showed improved health outcomes compared to patients not using ALL4IBD.



References:

1.https://rx.health/healthpromise/